Editas Medicine Inc
NASDAQ:EDIT
Intrinsic Value
The intrinsic value of one
EDIT
stock under the Base Case scenario is
2.37
USD.
Compared to the current market price of 7.46 USD,
Editas Medicine Inc
is
Overvalued by 68%.
The Intrinsic Value is calculated as the average of the two valuation methods:
Fundamental Analysis
EDIT Profitability Score
Profitability Due Diligence
Editas Medicine Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
Score
Editas Medicine Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.
EDIT Solvency Score
Solvency Due Diligence
Editas Medicine Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Score
Editas Medicine Inc's solvency score is 59/100. The higher the solvency score, the more solvent the company is.
Balance Sheet Decomposition
Editas Medicine Inc
| Current Assets | 357M |
| Cash & Short-Term Investments | 344M |
| Receivables | 5.1M |
| Other Current Assets | 7.3M |
| Non-Current Assets | 158M |
| Long-Term Investments | 93.1M |
| PP&E | 59.2M |
| Other Non-Current Assets | 5.3M |
| Current Liabilities | 60.1M |
| Accounts Payable | 9.5M |
| Accrued Liabilities | 42.4M |
| Other Current Liabilities | 8.2M |
| Non-Current Liabilities | 93.5M |
| Other Non-Current Liabilities | 93.5M |
EDIT Capital Structure
Editas Medicine Inc
| Market Capitalization | 514M USD | |
| Total Debt | 0 USD | |
| Minority Interest | 0 USD | |
| Preferred Equity | 0 USD | |
| Cash and Equivalents | 142M USD | |
| Short-Term Investments | 203M USD | |
| Enterprise Value | 169M USD | |
Wall St
Price Targets
EDIT Price Targets Summary
Editas Medicine Inc
According to Wall Street analysts, the average 1-year price target for
EDIT
is 13.32 USD
with a low forecast of 7.07 USD and a high forecast of 31.5 USD.
Ownership
EDIT Insider Trading
Buy and sell transactions by insiders
During the last 12 months Editas Medicine Inc insiders have not bought any shares, and sold 248k USD worth of shares. The last transaction was made on Mar 25, 2023 by Eaton Bruce (EVP, CBO AND CTO), who sold 898 USD worth of EDIT shares.
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
121k
USD
|
N/A
|
-121k
|
| 6 Months |
127k
USD
|
N/A
|
-127.2k
|
| 9 Months |
137k
USD
|
N/A
|
-137.1k
|
| 12 Months |
248k
USD
|
N/A
|
-248k
|
Shareholder Return
EDIT Return Decomposition
Main factors of price return
is not available
It is impossible to break down the market cap return as the net margin from 5 years ago is negative.
EDIT Price
Editas Medicine Inc
| Average Annual Return | 18% |
| Standard Deviation of Annual Returns | 91.19% |
| Max Drawdown | -92% |
| Market Capitalization | 514M USD |
| Shares Outstanding | 68 970 200 |
| Percentage of Shares Shorted | 30.82% |
Company Profile
Editas Medicine Inc
Country
Industry
Market Cap
Dividend Yield
Description
Editas Medicine, Inc. engages in the development and commercialization of genome editing technology. The company is headquartered in Cambridge, Massachusetts and currently employs 264 full-time employees. The company went IPO on 2016-02-03. The firm is focused on developing transformative gene editing medicines to treat a range of serious diseases. The company has developed a gene editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR) technology. CRISPR uses a protein-ribonucleic acid (RNA) complex composed of an enzyme, including either CRISPR associated protein 9 (Cas9) or CRISPR from Prevotella and Francisella 1 (Cpf1), bound to a guide RNA molecule designed to recognize a particular deoxyribonucleic acid (DNA) sequence. The firm is focused on both in vivo gene editing medicines, in which the medicine is injected or infused into the patient to edit the cells inside their body, and ex vivo gene-edited cell medicines, in which cells are edited with its technology. The firm's gene editing medicine programs include EDIT-101, EDIT-102, EDIT-103, EDIT-301 and EDIT-202.
Contact
IPO
Employees
Officers
The intrinsic value of one
EDIT
stock under the Base Case scenario is
2.37
USD.
Compared to the current market price of 7.46 USD,
Editas Medicine Inc
is
Overvalued by 68%.
